Inhibition of type I interferon responses by adenovirus serotype-dependent Gas6 binding.

about

Inhibition of type I interferon responses by adenovirus serotype-dependent Gas6 binding.

Item

http://www.wikidata.org/entity/Q47242905

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Inhibition of type I interferon responses by adenovirus serotype-dependent Gas6 binding.

@en

Inhibition of type I interferon responses by adenovirus serotype-dependent Gas6 binding.

@nl

type

Item

label

Inhibition of type I interferon responses by adenovirus serotype-dependent Gas6 binding.

@en

Inhibition of type I interferon responses by adenovirus serotype-dependent Gas6 binding.

@nl

prefLabel

Inhibition of type I interferon responses by adenovirus serotype-dependent Gas6 binding.

@en

Inhibition of type I interferon responses by adenovirus serotype-dependent Gas6 binding.

@nl

P1476

Inhibition of type I interferon responses by adenovirus serotype-dependent Gas6 binding.

@en

P2093

Christopher M Wiethoff

http://www.w3.org/2001/XMLSchema#string

Natalie F Nidetz

http://www.w3.org/2001/XMLSchema#string

Tom M Gallagher

http://www.w3.org/2001/XMLSchema#string

P2860

Gas6 is complexed to the soluble tyrosine kinase receptor Axl in human blood

The soluble serum protein Gas6 bridges virion envelope phosphatidylserine to the TAM receptor tyrosine kinase Axl to mediate viral entry

A capsid-encoded PPxY-motif facilitates adenovirus entry

Adenovirus Binding to Blood Factors Results in Liver Cell Infection and Hepatotoxicity

TAM receptors are pleiotropic inhibitors of the innate immune response

Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines

Adenovirus receptors.

Adenovirus protein VI mediates membrane disruption following capsid disassembly.

Potent immune responses and in vitro pro-inflammatory cytokine suppression by a novel adenovirus vaccine vector based on rare human serotype 28.

Substitution of adenovirus serotype 3 hexon onto a serotype 5 oncolytic adenovirus reduces factor X binding, decreases liver tropism, and improves antitumor efficacy.

P304

150-157

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VIROL.2017.12.016

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

515

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29288958

http://www.w3.org/2001/XMLSchema#string

P921

Adenoviridae

P932

6110086

http://www.w3.org/2001/XMLSchema#string